Эволюция спасительной терапии при биохимическом рецидиве рака предстательной железы после радикальной простатэктомии

Эволюция спасительной терапии при биохимическом рецидиве рака предстательной железы после радикальной простатэктомии

Автор: Павлов А.Ю., Дзидзария А.Г., Цыбульский А.Д., Мирзаханов Р.И., Халиль И.И.

Журнал: Вестник Российского научного центра рентгенорадиологии Минздрава России @vestnik-rncrr

Рубрика: Обзоры

Статья в выпуске: 2 т.23, 2023 года.

Бесплатный доступ

Биохимический рецидив (БХР) возникает в 30% случаев после радикальной простатэктомии (РПЭ) за 10-летний период наблюдения, однако, до сих пор эффективные варианты лечения таких пациентов остаются спорными. Несмотря на то, что простатический специфический антиген (ПСА) широко используется в качестве маркера прогрессирования заболевания после радикальной терапии, единый взгляд на его роль в качестве предиктора на общую и опухоль-специфичную выживаемость отсутствует. Учитывая тот факт, что БХР не всегда перетекает в клинический рецедив, клиницистам сложно определить необходимые сроки лечения, чтобы остановить или замедлить прогрессирование.Существуют несколько вариантов лечения БХР после РПЭ: адъювантная дистанционная лучевая терапия (АДЛТ), спасительная дистанционная лучевая терапия (СДЛТ) ложа удалённой предстательной железы и/или зоны регионарного лимфооттока, непрерывная или интермиттирующая спасительная андроген-депривационная терапия (АДТ), экспериментальные методики лечения, а также динамическое наблюдение. АДЛТ после РПЭ имеет свои преимущества с точки зрения выживаемости, однако, она не рекомендуется из-за значительных ранних и поздних лучевых осложнений. СДЛТ рекомендуется пациентам с БХР после РПЭ. При выборе наилучшей стратегии лечения необходимо учитывать сопутствующие заболевания, предпочтения пациентов, а также клинические и патоморфологические характеристики опухоли.

Еще

Рецидив, спасительная лучевая терапия, спасительная брахитерапия, биохимический рецидив, рак предстательной железы, простатэктомия

Короткий адрес: https://sciup.org/149143494

IDR: 149143494

Список литературы Эволюция спасительной терапии при биохимическом рецидиве рака предстательной железы после радикальной простатэктомии

  • Злокачественные новообразования в России в 2021 году (заболеваемость и смертность). Под редакцией Каприна АД, Старинского ВВ, Шахзадовой АО. М.: МНИОИ им. П.А.Герцена–филиал ФГБУ «НМИЦ радиологии» Минздрава России. 2022. 252 с.
  • National Comprehensive Cancer Network: Prostate Cancer (Version 2.2021), 2021. https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf
  • Roehl KA, Han M, Ramos CG, Antenor JA, Catalona WJ. Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results. J Urol. 2004 Sep;172(3):910-914. doi: 10.1097/01.ju.0000134888.22332.bb.
  • Freedland SJ, Humphreys EB, Mangold LA, Eisenberger M, Dorey FJ, Walsh PC, Partin AW. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA. 2005 Jul 27;294(4):433-439. doi: 10.1001/jama.294.4.433.
  • Artibani W, Porcaro AB, De Marco V, Cerruto MA, Siracusano S. Management of Biochemical Recurrence after Primary Curative Treatment for Prostate Cancer: A Review. Urol Int. 2018;100(3):251-262. doi: 10.1159/000481438.
  • Barlow SK, Oyekunle T, Janes JL, De Hoedt AM, Aronson WJ, Kane CJ, et al. Prostate weight and prostate cancer outcomes after radical prostatectomy: Results from the SEARCH cohort study. Prostate. 2022 Feb;82(3):366-372. doi: 10.1002/pros.24283
  • Cookson MS, Aus G, Burnett AL, Canby-Hagino ED, D'Amico AV, Dmochowski RR, et al. Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes. J Urol. 2007 Feb;177(2):540-545. doi: 10.1016/j.juro.2006.10.097.
  • Roach M 3rd, Hanks G, Thames H Jr, Schellhammer P, Shipley WU, Sokol GH, Sandler H. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys. 2006 Jul 15;65(4):965-974. doi: 10.1016/j.ijrobp.2006.04.029.
  • Hennrich U, Eder M. [68Ga]Ga-PSMA-11: The First FDA-Approved 68Ga-Radiopharmaceutical for PET Imaging of Prostate Cancer. Pharmaceuticals (Basel). 2021 Jul 23;14(8):713. doi: 10.3390/ph14080713.
  • Savir-Baruch B, Werner RA, Rowe SP, Schuster DM. PET Imaging for Prostate Cancer. Radiol Clin North Am. 2021 Sep;59(5):801-811. doi: 10.1016/j.rcl.2021.05.008.
  • Wang R, Shen G, Huang M, Tian R. The Diagnostic Role of 18F-Choline, 18F-Fluciclovine and 18F-PSMA PET/CT in the Detection of Prostate Cancer With Biochemical Recurrence: A Meta-Analysis. Front Oncol. 2021 Jun 17;11:684629. doi: 10.3389/fonc.2021.684629.
  • Mazrani W, Cook GJR, Bomanji J. Role of 68Ga and 18F PSMA PET/CT and PET/MRI in biochemical recurrence of prostate cancer: a systematic review of prospective studies. Nucl Med Commun. 2022 Jun 1;43(6):631-637. doi: 10.1097/MNM.0000000000001557.
  • Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council Trial. The Medical Research Council Prostate Cancer Working Party Investigators Group. Br J Urol. 1997 Feb;79(2):235-46. doi: 10.1046/j.1464-410x.1997.d01-6840.x.
  • Studer UE, Whelan P, Albrecht W, Casselman J, de Reijke T, Hauri D, et al. Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891. J Clin Oncol. 2006 Apr 20;24(12):1868-1876. doi: 10.1200/JCO.2005.04.7423.
  • Schröder FH, Kurth KH, Fossa SD, Hoekstra W, Karthaus PP, De Prijck L, Collette L. Early versus delayed endocrine treatment of T2-T3 pN1-3 M0 prostate cancer without local treatment of the primary tumour: final results of European Organisation for the Research and Treatment of Cancer protocol 30846 after 13 years of follow-up (a randomised controlled trial). Eur Urol. 2009 Jan;55(1):14-22. doi: 10.1016/j.eururo.2008.09.008.
  • Duchesne GM, Woo HH, Bassett JK, Bowe SJ, D'Este C, Frydenberg M, et al. Timing of androgen-deprivation therapy in patients with prostate cancer with a rising PSA (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial. Lancet Oncol. 2016 Jun;17(6):727-737. doi: 10.1016/S1470-2045(16)00107-8.
  • Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA. 1999 May 5;281(17):1591-1597. doi: 10.1001/jama.281.17.1591.
  • Slovin SF, Wilton AS, Heller G, Scher HI. Time to detectable metastatic disease in patients with rising prostate-specific antigen values following surgery or radiation therapy. Clin Cancer Res. 2005 Dec 15;11(24 Pt 1):8669-8673. doi: 10.1158/1078-0432.CCR-05-1668.
  • Okotie OT, Aronson WJ, Wieder JA, Liao Y, Dorey F, DeKERNION JB, Freedland SJ. Predictors of metastatic disease in men with biochemical failure following radical prostatectomy. J Urol. 2004 Jun;171(6 Pt 1):2260-2264. doi: 10.1097/01.ju.0000127734.01845.99.
  • Antonarakis ES, Chen Y, Elsamanoudi SI, Brassell SA, Da Rocha MV, Eisenberger MA, McLeod DG. Long-term overall survival and metastasis-free survival for men with prostate-specific antigen-recurrent prostate cancer after prostatectomy: analysis of the Center for Prostate Disease Research National Database. BJU Int. 2011 Aug;108(3):378-385. doi: 10.1111/j.1464-410X.2010.09878.x.
  • Virgo KS, Rumble RB, de Wit R, Mendelson DS, Smith TJ, Taplin ME, et al. Initial Management of Noncastrate Advanced, Recurrent, or Metastatic Prostate Cancer: ASCO Guideline Update. J Clin Oncol. 2021 Apr 10;39(11):1274-1305. doi: 10.1200/JCO.20.03256.
  • Lowrance WT, Breau RH, Chou R, Chapin BF, Crispino T, Dreicer R, et al. Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline PART I. J Urol. 2021 Jan;205(1):14-21. doi: 10.1097/JU.0000000000001375.
  • Lowrance WT, Breau RH, Chou R, Chapin BF, Crispino T, Dreicer R, et al. Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline PART II. J Urol. 2021 Jan;205(1):22-29. doi: 10.1097/JU.0000000000001376.
  • Huggins C, Hodges CV. Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. J Urol. 2002 Jul;168(1):9-12. doi: 10.1016/s0022-5347(05)64820-3.
  • Denmeade SR, Isaacs JT. A history of prostate cancer treatment. Nat Rev Cancer. 2002 May;2(5):389-396. doi: 10.1038/nrc801.
  • Roach M 3rd, Bae K, Speight J, Wolkov HB, Rubin P, Lee RJ, et al. Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610. J Clin Oncol. 2008 Feb 1;26(4):585-591. doi: 10.1200/JCO.2007.13.9881.
  • Horwitz EM, Bae K, Hanks GE, Porter A, Grignon DJ, Brereton HD, et al. Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J Clin Oncol. 2008 May 20;26(15):2497-2504. doi: 10.1200/JCO.2007.14.9021.
  • Bolla M, Van Tienhoven G, Warde P, Dubois JB, Mirimanoff RO, Storme G, et al. External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. Lancet Oncol. 2010 Nov;11(11):1066-1073. doi: 10.1016/S1470-2045(10)70223-0.
  • Cornford P, Bellmunt J, Bolla M, Briers E, De Santis M, Gross T, et al. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer. Eur Urol. 2017 Apr;71(4):630-642. doi: 10.1016/j.eururo.2016.08.002.
  • Bruchovsky N, Rennie PS, Coldman AJ, Goldenberg SL, To M, Lawson D. Effects of androgen withdrawal on the stem cell composition of the Shionogi carcinoma. Cancer Res. 1990 Apr 15;50(8):2275-2282.
  • Akakura K, Bruchovsky N, Goldenberg SL, Rennie PS, Buckley AR, Sullivan LD. Effects of intermittent androgen suppression on androgen-dependent tumors. Apoptosis and serum prostate-specific antigen. Cancer. 1993;71:2782–2790.
  • Sato N, Gleave ME, Bruchovsky N, Rennie PS, Goldenberg SL, Lange PH, Sullivan LD. Intermittent androgen suppression delays progression to androgen-independent regulation of prostate-specific antigen gene in the LNCaP prostate tumour model. J Steroid Biochem Mol Biol. 1996 May;58(2):139-146. doi: 10.1016/0960-0760(96)00018-0.
  • Keating NL, O'Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol. 2006 Sep 20;24(27):4448-4456. doi: 10.1200/JCO.2006.06.2497.
  • D'Amico AV, Denham JW, Crook J, Chen MH, Goldhaber SZ, Lamb DS, et al. Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J Clin Oncol. 2007 Jun 10;25(17):2420-2425. doi: 10.1200/JCO.2006.09.3369.
  • Spry NA, Galvão DA, Davies R, La Bianca S, Joseph D, Davidson A, Prince R. Long-term effects of intermittent androgen suppression on testosterone recovery and bone mineral density: results of a 33-month observational study. BJU Int. 2009 Sep;104(6):806-812. doi: 10.1111/j.1464-410X.2009.08458.x.
  • Green HJ, Pakenham KI, Headley BC, Yaxley J, Nicol DL, Mactaggart PN, et al. Altered cognitive function in men treated for prostate cancer with luteinizing hormone-releasing hormone analogues and cyproterone acetate: a randomized controlled trial. BJU Int. 2002 Sep;90(4):427-432. doi: 10.1046/j.1464-410x.2002.02917.x.
  • Cherrier MM, Rose AL, Higano C. The effects of combined androgen blockade on cognitive function during the first cycle of intermittent androgen suppression in patients with prostate cancer. J Urol. 2003 Nov;170(5):1808-1811. doi: 10.1097/01.ju.0000091640.59812.83.
  • Higano C, Shields A, Wood N, Brown J, Tangen C. Bone mineral density in patients with prostate cancer without bone metastases treated with intermittent androgen suppression. Urology. 2004 Dec;64(6):1182-1186. doi: 10.1016/j.urology.2004.07.019.
  • Harle LK, Maggio M, Shahani S, Braga-Basaria M, Basaria S. Endocrine complications of androgen-deprivation therapy in men with prostate cancer. Clin Adv Hematol Oncol. 2006 Sep;4(9):687-696. PMID: 17099626.
  • Crook JM, O'Callaghan CJ, Duncan G, Dearnaley DP, Higano CS, Horwitz EM, et al. Intermittent androgen suppression for rising PSA level after radiotherapy. N Engl J Med. 2012 Sep 6;367(10):895-903. doi: 10.1056/NEJMoa1201546.
  • Trock BJ, Han M, Freedland SJ, Humphreys EB, DeWeese TL, Partin AW, Walsh PC. Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy. JAMA. 2008 Jun 18;299(23):2760-2769. doi: 10.1001/jama.299.23.2760.
  • Thompson IM, Tangen CM, Paradelo J, Lucia MS, Miller G, Troyer D, et al. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. J Urol. 2009 Mar;181(3):956-962. doi: 10.1016/j.juro.2008.11.032
  • Bolla M, van Poppel H, Tombal B, Vekemans K, Da Pozzo L, de Reijke TM, et al. European Organisation for Research and Treatment of Cancer, Radiation Oncology and Genito-Urinary Groups. Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911). Lancet. 2012 Dec 8;380(9858):2018-2027. doi: 10.1016/S0140-6736(12)61253-7.
  • Wiegel T, Bartkowiak D, Bottke D, Bronner C, Steiner U, Siegmann A, et al. Adjuvant radiotherapy versus wait-and-see after radical prostatectomy: 10-year follow-up of the ARO 96-02/AUO AP 09/95 trial. Eur Urol. 2014 Aug;66(2):243-250. doi: 10.1016/j.eururo.2014.03.011.
  • Tendulkar RD, Agrawal S, Gao T, Efstathiou JA, Pisansky TM, Michalski JM, et al. Contemporary Update of a Multi-Institutional Predictive Nomogram for Salvage Radiotherapy After Radical Prostatectomy. J Clin Oncol. 2016 Oct 20;34(30):3648-3654. doi: 10.1200/JCO.2016.67.9647.
  • Stish BJ, Pisansky TM, Harmsen WS, Davis BJ, Tzou KS, Choo R, Buskirk SJ. Improved Metastasis-Free and Survival Outcomes With Early Salvage Radiotherapy in Men With Detectable Prostate-Specific Antigen After Prostatectomy for Prostate Cancer. J Clin Oncol. 2016 Nov 10;34(32):3864-3871. doi: 10.1200/JCO.2016.68.3425.
  • Gandaglia G, Briganti A, Clarke N, Karnes RJ, Graefen M, Ost P, Zietman AL, Roach M 3rd. Adjuvant and Salvage Radiotherapy after Radical Prostatectomy in Prostate Cancer Patients. Eur Urol. 2017 Nov;72(5):689-709. doi: 10.1016/j.eururo.2017.01.039.
  • Ghadjar P, Hayoz S, Bernhard J, Zwahlen DR, Hölscher T, Gut P, et al. Swiss Group for Clinical Cancer Research (SAKK). Dose-intensified Versus Conventional-dose Salvage Radiotherapy for Biochemically Recurrent Prostate Cancer After Prostatectomy: The SAKK 09/10 Randomized Phase 3 Trial. Eur Urol. 2021 Sep;80(3):306-315. doi: 10.1016/j.eururo.2021.05.033.
  • Ohri N, Dicker AP, Trabulsi EJ, Showalter TN. Can early implementation of salvage radiotherapy for prostate cancer improve the therapeutic ratio? A systematic review and regression meta-analysis with radiobiological modelling. Eur J Cancer. 2012 Apr;48(6):837-844. doi: 10.1016/j.ejca.2011.08.013.
  • King CR. The timing of salvage radiotherapy after radical prostatectomy: a systematic review. Int J Radiat Oncol Biol Phys. 2012 Sep 1;84(1):104-111. doi: 10.1016/j.ijrobp.2011.10.069.
  • Pisansky TM, Agrawal S, Hamstra DA, Koontz BF, Liauw SL, Efstathiou JA, et al. Salvage Radiation Therapy Dose Response for Biochemical Failure of Prostate Cancer After Prostatectomy-A Multi-Institutional Observational Study. Int J Radiat Oncol Biol Phys. 2016 Dec 1;96(5):1046-1053. doi: 10.1016/j.ijrobp.2016.08.043.
  • Shelan M, Abo-Madyan Y, Welzel G, Bolenz C, Kosakowski J, Behnam N, et al. Dose-escalated salvage radiotherapy after radical prostatectomy in high risk prostate cancer patients without hormone therapy: outcome, prognostic factors and late toxicity. Radiat Oncol. 2013 Nov 27;8:276. doi: 10.1186/1748-717X-8-276.
  • Kneebone A, Fraser-Browne C, Duchesne GM, Fisher R, Frydenberg M, Herschtal A, et al. Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG 08.03/ANZUP RAVES): a randomised, controlled, phase 3, non-inferiority trial. Lancet Oncol. 2020 Oct;21(10):1331-1340. doi: 10.1016/S1470-2045(20)30456-3.
  • Malone S, Croke J, Roustan-Delatour N, Belanger E, Avruch L, Malone C, et al. Postoperative radiotherapy for prostate cancer: a comparison of four consensus guidelines and dosimetric evaluation of 3D-CRT versus tomotherapy IMRT. Int J Radiat Oncol Biol Phys. 2012 Nov 1;84(3):725-732. doi: 10.1016/j.ijrobp.2011.12.081.
  • Qi X, Li HZ, Gao XS, Qin SB, Zhang M, Li XM, et al. Toxicity and Biochemical Outcomes of Dose-Intensified Postoperative Radiation Therapy for Prostate Cancer: Results of a Randomized Phase III Trial. Int J Radiat Oncol Biol Phys. 2020 Feb 1;106(2):282-290. doi: 10.1016/j.ijrobp.2019.09.047.
  • Reis Ferreira M, Khan A, Thomas K, Truelove L, McNair H, Gao A, et al. Phase 1/2 Dose-Escalation Study of the Use of Intensity Modulated Radiation Therapy to Treat the Prostate and Pelvic Nodes in Patients With Prostate Cancer. Int J Radiat Oncol Biol Phys. 2017 Dec 1;99(5):1234-1242. doi: 10.1016/j.ijrobp.2017.07.041.
  • Han S, Woo S, Kim YJ, Suh CH. Impact of 68Ga-PSMA PET on the Management of Patients with Prostate Cancer: A Systematic Review and Meta-analysis. Eur Urol. 2018 Aug;74(2):179-190. doi: 10.1016/j.eururo.2018.03.030.
  • Pollack A, Karrison TG, Balogh AG, Low D, Bruner DW, Wefel JS, et al. Short term androgen deprivation therapy without or with pelvic lymph node treatment added to prostate bed only salvage radiotherapy: the NRG Oncology/RTOG 0534 SPPORT trial. Int J Radiat Oncol Biol Phys. 2018;102:1605. DOI:10.1016/j.ijrobp.2018.08.052.
  • Brand DH, Parker JI, Dearnaley DP, Eeles R, Huddart R, Khoo V, et al. Patterns of recurrence after prostate bed radiotherapy. Radiother Oncol. 2019 Dec;141:174-180. doi: 10.1016/j.radonc.2019.09.007.
  • Cooperberg MR, Carroll PR. Trends in Management for Patients With Localized Prostate Cancer, 1990-2013. JAMA. 2015 Jul 7;314(1):80-82. doi: 10.1001/jama.2015.6036.
  • Wilt TJ, Brawer MK, Jones KM, Barry MJ, Aronson WJ, Fox S, Gingrich JR, et al. Prostate Cancer Intervention versus Observation Trial (PIVOT) Study Group. Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med. 2012 Jul 19;367(3):203-213. doi: 10.1056/NEJMoa1113162.
  • Mullins JK, Feng Z, Trock BJ, Epstein JI, Walsh PC, Loeb S. The impact of anatomical radical retropubic prostatectomy on cancer control: the 30-year anniversary. J Urol. 2012 Dec;188(6):2219-2224. doi: 10.1016/j.juro.2012.08.028.
  • Stephenson AJ, Scardino PT, Kattan MW, Pisansky TM, Slawin KM, Klein EA, et al. Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol. 2007 May 20;25(15):2035-2041. doi: 10.1200/JCO.2006.08.9607.
  • Pisansky TM, Kozelsky TF, Myers RP, Hillman DW, Blute ML, Buskirk SJ, et al. Radiotherapy for isolated serum prostate specific antigen elevation after prostatectomy for prostate cancer. J Urol. 2000 Mar;163(3):845-850. PMID: 10687990.
  • Valicenti RK, Thompson I Jr, Albertsen P, Davis BJ, Goldenberg SL, Wolf JSet al. American Society for Radiation Oncology/American Urological Association. Adjuvant and salvage radiation therapy after prostatectomy: American Society for Radiation Oncology/American Urological Association guidelines. Int J Radiat Oncol Biol Phys. 2013 Aug 1;86(5):822-828. doi: 10.1016/j.ijrobp.2013.05.029.
  • Pilepich MV, Caplan R, Byhardt RW, Lawton CA, Gallagher MJ, Mesic JB, et al. Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group Protocol 85-31. J Clin Oncol. 1997 Mar;15(3):1013-1021. doi: 10.1200/JCO.1997.15.3.1013.
  • Bolla M, Gonzalez D, Warde P, Dubois JB, Mirimanoff RO, Storme G, et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med. 1997 Jul 31;337(5):295-300. doi: 10.1056/NEJM199707313370502.
  • Hanks GE, Pajak TF, Porter A, Grignon D, Brereton H, Venkatesan V, Horwitz EM, Lawton C, Rosenthal SA, Sandler HM, Shipley WU; Radiation Therapy Oncology Group. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02. J Clin Oncol. 2003 Nov 1;21(21):3972-3978. doi: 10.1200/JCO.2003.11.023.
  • Iversen P, Tyrrell CJ, Kaisary AV, Anderson JB, Baert L, Tammela T, et al. Casodex (bicalutamide) 150-mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow-up of 4 years. Urology. 1998 Mar;51(3):389-396. doi: 10.1016/s0090-4295(98)00004-1.
  • Tyrrell CJ, Kaisary AV, Iversen P, Anderson JB, Baert L, Tammela T, et al. A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. Eur Urol. 1998;33(5):447-456. doi: 10.1159/000019634.
  • Shipley WU, Hunt D, Lukka HR, Major P, Heney NM, Grignon D, et al. Initial report of RTOG 9601, a phase III trial in prostate cancer: effect of anti-androgen therapy (AAT) with bicalutamide during and after radiation therapy (RT) on freedom from progression and incidence of metastatic disease in patients following radical prostatectomy (RP) with pT2-3, N0 disease and elevated PSA levels. J Clin Oncol. 2011;29(7 suppl):1.
  • Shipley WU, Seiferheld W, Lukka HR, Major PP, Heney NM, Grignon DJ, et al.; NRG Oncology RTOG. Radiation with or without Antiandrogen Therapy in Recurrent Prostate Cancer. N Engl J Med. 2017 Feb 2;376(5):417-428. doi: 10.1056/NEJMoa1607529.
  • Dess RT, Sun Y, Jackson WC, Jairath NK, Kishan AU, Wallington DG, et al. Association of Presalvage Radiotherapy PSA Levels After Prostatectomy With Outcomes of Long-term Antiandrogen Therapy in Men With Prostate Cancer. JAMA Oncol. 2020 May 1;6(5):735-743. doi: 10.1001/jamaoncol.2020.0109.
  • Pollack A, Karrison TG, Balogh AG, Gomella LG, Low DA, Bruner DW, et al. The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG Oncology/RTOG 0534 SPPORT): an international, multicentre, randomised phase 3 trial. Lancet. 2022 May 14;399(10338):1886-1901. doi: 10.1016/S0140-6736(21)01790-6.
  • Bolla M, van Poppel H, Collette L, van Cangh P, Vekemans K, Da Pozzo L, et al.; European Organization for Research and Treatment of Cancer. Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet. 2005 Aug 13-19;366(9485):572-578. doi: 10.1016/S0140-6736(05)67101-2.
  • Wiegel T, Bottke D, Steiner U, Siegmann A, Golz R, Störkel S, et al. Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95. J Clin Oncol. 2009 Jun 20;27(18):2924-2930. doi: 10.1200/JCO.2008.18.9563.
  • Thompson IM Jr, Tangen CM, Paradelo J, Lucia MS, Miller G, Troyer D, et al. Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. JAMA. 2006 Nov 15;296(19):2329-2335. doi: 10.1001/jama.296.19.2329.
  • Parker C, Clarke N, Logue J, Payne H, Catton C, Kynaston H, et al.; RADICALS Trial Management Group. RADICALS (Radiotherapy and Androgen Deprivation in Combination after Local Surgery). Clin Oncol (R Coll Radiol). 2007 Apr;19(3):167-171. doi: 10.1016/j.clon.2007.01.001.
Еще
Статья научная
SciUp 2024 © 2024 ©